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Abstract: Partial epilepsy comprises simple partial seizures, complex partial seizures, and   
secondarily generalized seizures, and covers more than 60% of patients with epilepsy. Antiepi-
leptic drugs are generally considered to be the major therapeutic intervention for epilepsy but, 
despite a broad range of commonly used antiepileptic drugs, approximately 30% of adult patients 
and approximately 25% of children with epilepsy have inadequate seizure control. Eslicarba-
zepine acetate (ESL) is a novel voltage-gated sodium channel-blocking agent with presumed 
good safety and efficacy for adjunctive treatment of patients with drug-resistant partial epilepsy. 
ESL is a prodrug of eslicarbazepine (the active entity responsible for pharmacologic effects), 
and is rapidly and extensively hydrolyzed during first pass by liver esterases after oral admin-
istration. The half-life of eslicarbazepine at steady-state plasma concentrations is 20–24 hours, 
compatible with once-daily administration. ESL 800 mg and 1200 mg significantly reduces 
seizure frequency and shows a favorable safety profile in adult patients with drug-resistant 
partial-onset seizures, as demonstrated in previous Phase II and III trials. In children, ESL 
showed a clear dose-dependent decrease in seizure frequency with good tolerability. The most 
commonly reported adverse events associated with ESL are dizziness, somnolence, nausea, 
diplopia, headache, vomiting, blurred vision, vertigo, and fatigue. In conclusion, these charac-
teristics suggest that ESL might be a valid and well tolerated treatment option for patients with 
drug-resistant partial-onset epilepsy. The convenience of once-daily dosing and a short, simple 
titration regimen would be of special interest for children, although conclusive published data 
are lacking to date. Hence, there is an urgent need to establish the therapeutic value of ESL in 
this special population in the near future.
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Introduction
Partial epilepsy comprises simple partial seizures, complex partial seizures, and 
  secondarily generalized seizures, and covers more than 60% of patients with   epilepsy.1 
Antiepileptic drugs (AEDs) are generally considered to be the major therapeutic 
intervention for epilepsy, and first-line pharmacologic treatment of partial seizures 
includes levetiracetam, carbamazepine, oxcarbazepine, sodium valproate, phenytoin, 
and lamotrigine.
Despite a broad range of commonly used AEDs, approximately 30% of adult 
patients with epilepsy have inadequate seizure control, and approximately 25% of chil-
dren with epilepsy experience drug resistance or encounter clinically significant adverse 
effects.2,3 Although these suboptimal results usually lead to use of a combination of 
AEDs, a substantial proportion of patients with epilepsy continue to be therapy-resistant Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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despite extension of pharmacotherapy. The aforementioned 
data have led to widely accepted recommendations for phar-
macologic therapy regimes in patients with hard-to-handle 
seizures for whom epilepsy surgery is not indicated. In the 
case of a nonresponder to the first AED with the highest tol-
erated dose, the recommended next step would be to titrate 
upwards with a second AED, while tapering off the first to 
switch the patient to an equipotent monotherapy.4 Of note, 
there is a growing body of evidence that patients initially 
not responding to AED treatment possibly achieve seizure 
freedom with implementation of an AED with an alternative 
mode of action as a substitute for the prior established drug.5 
Finally, previously published data have suggested that in the 
event of treatment resistance despite two appropriate AED 
monotherapy regimens, a third monotherapy trial is expected 
to have very limited success.6,7 As a consequence, combina-
tion therapy is preferred in the management of drug-resistant 
epilepsy in adults and children nowadays.
One has to bear in mind that the ongoing introduction 
of diverse new AEDs for adjunctive use in refractory partial 
epilepsy has considerably increased the number of potential 
pharmacologic combinations and interactions in a confusing 
way. Therefore, the attending physician is urged to appraise 
various factors when selecting adequate adjunctive agents for 
polytherapy, comprising efficacy, tolerability profile (adverse 
effects, mode of action, drug interactions, eg, between AEDs 
and oral contraceptives), and, especially in childhood, ease of 
administration. Therefore, there is still the need for develop-
ment of further AEDs to reduce seizure frequency and improve 
the safety profile in adults and children with epilepsy.8–10
Eslicarbazepine acetate (ESL), a voltage-gated sodium 
channel (VGSC)-blocking agent, is a third-generation, 
single-enantiomer member of the commonly prescribed 
first-line dibenz[b,f]azepine family of AEDs (including 
carbamazepine [first generation] and oxcarbazepine [second 
generation])11 with presumed good safety and efficacy for 
adjunctive treatment of patients with partial epilepsy. In the 
resting state, the affinity of eslicarbazepine for the VGSC 
is comparable with that of carbamazepine, with suggested 
higher inhibitory selectivity for rapidly firing neurons over 
those displaying normal activity.
After oral administration, ESL is immediately and 
extensively hydrolyzed to the pharmacologically active entity, 
eslicarbazepine, during first pass, resulting in an effective 
half-life of 20–24 hours at steady-state plasma concentra-
tions compatible with once-daily administration. Because 
eslicarbazepine is chemically related to   carbamazepine 
and oxcarbazepine, with differences at the 10,11 position, 
eslicarbazepine is not susceptible to metabolic autoinduction, 
and might have a favorable safety profile and a low drug 
interaction potential.12–21 Unlike oxcarbazepine, which 
is metabolized to both (S)-licarbazepine (80%) and (R)-
licarbazepine (20%), eslicarbazepine is metabolized solely 
to (S)-licarbazepine, although it subsequently undergoes a 
minor chiral inversion (through oxidation to oxcarbazepine) 
to (R)-licarbazepine.22 Other than oxcarbazepine, ESL avoids 
unnecessary production of enantiomers or diastereoisomers 
of metabolites and their conjugates.23 After Phase III trials 
were completed (mainly in Europe and South America), ESL 
was approved by the European Medicines Agency and is now 
available in most European countries as adjunct therapy for 
adult patients with refractory partial seizures.24 Of note, no 
study has been conducted in the US so far.
This paper reviews the efficacy and safety profile of ESL 
in adults and children with partial epilepsy. The authors 
conducted a Medline literature search for all publications on 
eslicarbazepine in clinical and experimental trials, in parallel 
with a search of congress abstracts.
Mechanism of action
To date, the anticonvulsant efficacy of eslicarbazepine has 
been evaluated in several animal models, and has proven but 
weak properties against clonic seizures induced by pentyle-
netetrazol, bicuculline, picrotoxine, and 4-aminopyridine.15,18,25 
Unfortunately, the precise underlying mechanism of action 
of eslicarbazepine remains obscure. Eslicarbazepine inhibits, 
similar to carbamazepine and oxcarbazepine, the release of dif-
ferent neurotransmitters/neuromodulators, namely glutamate, 
gamma-aminobutyric acid (GABA), aspartate, and dopamine in 
rat striatal slices. Electrophysiologic studies indicate a competi-
tive interaction of eslicarbazepine acetate and eslicarbazepine 
with site 2 of the inactivated state of a VGSC in vitro, thus 
preventing its reversion to the active state and repetitive neu-
ronal firing. Furthermore, tonic extension seizures in maximal 
electroshock tests in rats and mice and limbic seizures in the 
corneal-kindled mouse and amygdala-kindled rat are known to 
be blocked. In addition, analgesic activity in the formalin paw 
test and in the chronic constriction nerve injury pain model of 
neuropathic pain in mice has been shown.11,14,18,25,26
Pharmacokinetics  
and pharmacodynamics
The pharmacokinetic and pharmacodynamic profile of 
eslicarbazepine, as well as the mechanisms of action, differ 
from those of the well known and frequently used VGSC 
blockers.16,27 ESL (BIA 2-093, S-(-)-10-acetoxy-10,11-dNeuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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ihydro-5H-dibenz/b,f/azepine-5-carboxamide) is a novel 
AED that shares with carbamazepine and oxcarbazepine 
the dibenzazepine nucleus bearing the 5-carboxamide 
substitute, but is structurally different at the 10,11 posi-
tion. This molecular variation should lead to the reduction 
of toxic metabolites, enantiomers, or diastereoisomers 
without losing pharmacologic activity. The absorption of 
ESL from the gastrointestinal tract is high, and after oral 
administration, ESL is extensively metabolized to the 
main metabolite, eslicarbazepine, the S(+) enantiomer of 
licarbazepine (S-licarbazepine, (S)-(+)-10,11-dihydro-
10-hydroxy-5H-dibenz/b,f/azepine-5-  carboxamide). 
R-licarbazepine and oxcarbazepine (formed by nonmi-
crosomal cytochrome (CYP) P450-mediated metabolism) 
are minor metabolites, corresponding, respectively, to 
approximately 5% and 1% of systemic exposure. Of 
note, the plasma concentrations of eslicarbazepine have 
been found below the limit of   quantification of the assay 
(10 ng/mL), with approximately 30% of eslicarbazepine 
bound to plasma proteins. Eslicarbazepine competitively 
interacts with site 2 of the inactivated VGSC (with similar 
affinity to that of carbamazepine), but shows a three-fold 
lower affinity for the resting state of the channel, suggesting 
higher inhibitory selectivity of eslicarbazepine for rapidly 
firing neurons. Glucuronidation and renal excretion are 
the main metabolic pathways for eslicarbazepine. Minor 
metabolites in urine are R-licarbazepine, oxcarbazepine, 
and their glucuronyl conjugates, with renal impairment 
significantly decreasing the clearance of metabolites. The 
mean renal clearance from plasma reaches 20–30 mL/min, 
and the postdose amount recovered in urine is approxi-
mately 20% and 40% within 12 and 24 hours, respectively. 
Previous studies in human hepatocytes show no induction 
of CYP1A2, CYP3A4, or Phase II hepatic enzymes, and 
this seems not to be affected by mild or moderate liver 
impairment. Across a dose range of 400–2400 mg/day, 
the pharmacokinetics of eslicarbazepine are linear and 
show dose proportionality. In healthy subjects, maximum 
observed plasma concentrations were attained at 1–4 hours 
postdose after single-dose administration, and steady-state 
plasma concentrations were attained at 4–5 days, reflect-
ing a half-life of 20–24 hours.12,28 According to pharma-
cokinetic analyses of data from Phase III studies in adults 
with epilepsy, the clearance of carbamazepine, phenytoin, 
topiramate, clobazam, gabapentin, phenobarbital, levetirac-
etam, and sodium valproate seems to be unaffected by ESL 
Furthermore, there is a growing body of evidence that aceta-
zolamide, clobazam, clonazepam, gabapentin, lamotrigine, 
phenobarbital, phenytoin, primidone, and sodium valproate 
do not interfere with metabolism of ESL.16,24,28–30
Efficacy of ESL
The placebo-controlled and open-label studies of ESL per-
formed to date are summarized in Table 1. An early Phase II 
multicenter, double-blind, randomized, placebo-controlled 
study was conducted in 143 refractory patients aged 18–65 
years with at least four partial-onset seizures per month. The 
study consisted of a 12-week treatment period followed by a 
one-week tapering off phase. Patients were randomly assigned 
to one of three treatment groups, ie, ESL once daily (n = 50), 
ESL twice daily (n = 46), or placebo (n = 47). The daily dose 
was titrated from 400 mg to 800 mg and to 1200 mg at four-
week intervals. The proportion of responders (patients with 
$50% seizure reduction) was the primary endpoint. The 
intention-to-treat population included all randomized patients 
with at least one administration of study medication, while the 
per protocol population included all patients who completed 
the study. Testing for superiority of ESL versus placebo (with 
regard to the proportion of responders) was based on the 
intention-to-treat population, applying the one-sided t-test. 
ESL was found to be efficacious and well tolerated in adults 
with refractory partial-onset seizures. The percentage of 
responders versus baseline showed a   statistically significant 
difference between the once-daily and placebo groups (54% 
versus 28%; 90% confidence interval [CI]: -infinity, -14; 
P = 0.008). The difference between the twice-daily (41%) 
and placebo groups did not reach statistical significance (90% 
Table 1 Responder rates and decrease in seizure frequency for 
ESL from three placebo-controlled Phase III trials (intent-to-treat 
population)
Study ESL dose  
(mg/day)
Responder  
rates (%)¹
Decrease  
in seizure 
frequency²
Elger et al24 400 23.0 26.0
800 34.0* 36.0*
1200 43.0** 45.0**
Placebo 20.0 16.0
Ben-Menachem  
et al16
400
800
17.0
40.0**
18.7
32.6**
1200 37.1* 32.8**
Placebo 13.0   0.8
Gil-Nagel  
et al30
800
1200
34.5
37.7*
37.9
41.9*
  Placebo 22.6 17.0
Notes: ¹Seizure frequency reduction $50%; ²Median relative reduction in seizure 
frequency during the maintenance period; *P , 0.05 versus placebo; **P  ,  0.001 
versus placebo.
Abbreviation: ESL, eslicarbazepine acetate.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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CI: -infinity, -1; P = 0.12). A significantly higher proportion 
of responders in weeks 5–8 was found in the once-daily group 
than in the twice-daily group (58% versus 33%, respectively; 
P = 0.022). At the end of the 12-week treatment, the number 
of seizure-free patients in the once-daily and twice-daily 
groups was 24%, which was significantly different from the 
placebo group. The incidence of adverse effects was similar 
between the treatment groups, and no serious drug-related 
adverse effects occurred.31
Three Phase III trials have been completed in a total 
of 1050 patients enrolled at 125 sites in 23 countries 
(Tables 1 and 2). All three studies used a multicenter, random-
ized, double-blind, placebo-controlled, parallel-group design, 
and included patients with at least four simple or complex 
partial-onset seizures per four weeks despite treatment with 
one to three AEDs. The primary analysis of efficacy was 
based on the intention-to-treat population using an analysis 
of covariance that models seizure frequency as a function of 
baseline seizure frequency and treatment. Supportive assess-
ments were performed per protocol. Each study consisted 
of an eight-week baseline period, followed by double-blind 
two-week titration and a double-blind 12-week maintenance 
period. There were three ESL dose groups (400 mg, 800 mg, 
or 1200 mg once daily) in two studies but only two ESL 
dose groups (800 mg and 1200 mg once daily) in one study. 
Between 64% and 75% of patients in each of the Phase III 
studies were using two concomitant AEDs, the most common 
of which was carbamazepine. One was a double-blind, pla-
cebo-controlled, parallel-group, multicenter study consisting 
of an eight-week baseline period, after which patients were 
randomized to placebo (n = 87) or once-daily ESL 800 mg 
(n = 85) or 1200 mg (n = 80). Patients received a half dose 
during the two weeks preceding a 12-week maintenance 
period. Seizure frequency over the maintenance period was 
significantly (P , 0.05) lower than for placebo in both ESL 
groups. The responder rate was 23% (placebo), 35% (ESL 
800 mg), and 38% (ESL 1200 mg). Median relative reduction 
in seizure frequency was 17% (placebo), 38% (ESL 800 mg), 
and 42% (ESL 1200 mg), as shown in Table 1. The most com-
mon adverse effects (.10%) were dizziness, somnolence, 
headache, and nausea. The majority of adverse effects were 
of mild or moderate severity. The authors concluded that 
once-daily treatment with ESL 800 mg and 1200 mg was 
effective and generally well tolerated.30
The other multicenter, parallel-group study consisted 
of an eight-week, single-blind, placebo baseline phase, 
after which patients were randomized to placebo (n = 102) 
or   once-daily ESL 400 mg (n = 100), 800 mg (n = 98), or 
1200 mg (n = 102) in the double-blind treatment phase. The 
ESL starting dose was 400 mg. Thereafter, ESL was titrated 
in weekly 400 mg steps to the full maintenance dose (12 
weeks). ESL 400 mg, 800 mg, and 1200 mg once daily was 
well tolerated and more effective than placebo in patients who 
were refractory to treatment with one or two concomitant 
AEDs (Table 1).24
Another double-blind, parallel-group, multicenter study 
consisted of an eight-week observational baseline period, 
after which patients were randomized to placebo (n = 100) 
or once-daily ESL 400 mg (n = 96), 800 mg (n = 101), or 
1200 mg (n = 98). Patients then entered a 14-week, double-
blind treatment phase. All patients started on their full 
maintenance dose except for those in the ESL 1200 mg 
group who received once-daily ESL 800 mg for two weeks 
before reaching their full maintenance dose. Four-week 
seizure frequency (the primary endpoint) over the 14-week, 
double-blind treatment period was significantly lower than 
for placebo in the ESL 800 mg and 1200 mg groups (each 
P # 0.001). Responder rate ($50% reduction in seizure 
frequency) was 13.0% (placebo), 16.7% (ESL 400 mg), 
40.0% (ESL 800 mg, P # 0.001), and 37.1% (ESL 1200 mg, 
P # 0.001). Median relative reduction in seizure frequency 
was 0.8% (placebo), 18.7% (ESL 400 mg), 32.6% (ESL 
800 mg, P # 0.001 versus ESL 400 mg and placebo), and 
32.8% (ESL 1200 mg, P # 0.001 versus ESL 400 mg and 
placebo, Table 1). Discontinuation rates due to adverse effects 
were 3.0% (placebo), 12.5% (ESL 400 mg), 18.8% (ESL 
800 mg), and 26.5% (ESL 1200 mg). The most common 
(.5%) adverse effects in any group were dizziness, somno-
lence, headache, nausea, diplopia, abnormal coordination, 
vomiting, blurred vision, and fatigue. The majority of adverse 
effects were of mild or moderate severity. Treatment with 
once-daily ESL 800 mg and 1200 mg was more effective 
Table  2  Summary  of  adverse  events  from  three  placebo-
controlled Phase III trials
Adverse events Percentage of patients
All doses of ESL 
(n = 760)
Placebo  
(n = 289)
Any adverse event
  Dizziness 22.2 7.4
  Somnolence 13.2 9.4
  Headache 11.0 8.8
  Nausea 10.3 1.3
  Vomiting   7.9 3.2
  Diplopia   7.3 1.7
Serious adverse events
  Deaths   0.0 0.3
Abbreviations: n, number of patients; ESL, eslicarbazepine acetate.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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than placebo (Table 1) and generally well tolerated in patients 
with partial-onset seizures refractory to treatment with one 
to three concomitant AEDs.16
To evaluate the long-term efficacy and safety of once-
daily ESL as adjunctive therapy for partial-onset seizures 
in adults with epilepsy, a one-year, open-label treatment 
extension with ESL in patients who completed a placebo-
controlled pivotal study was conducted. The starting dose was 
800 mg once daily for four weeks and, thereafter, the dose 
could be titrated up or down, and doses of concomitant AEDs 
had to be kept stable. Overall, 314 patients were enrolled. The 
intent-to-treat population consisted of 312 patients, of whom 
239 (76.6%) completed one year of treatment. The median 
ESL dose was 800 mg once daily. Compared with baseline, 
median seizure frequency decreased by 39% during the first 
four weeks, and by 48%–56% thereafter. The responder rate 
was 41% during weeks 1–4 and ranged between 48% and 
53% thereafter. The proportion of seizure-free patients per 
12-week interval ranged between 8.7% and 12.5%. Qual-
ity of life, as measured by the Quality of Life in Epilepsy 
Inventory-31, and depressive symptoms, as measured by the 
Montgomery Asberg Depression Rating Scale, improved 
significantly compared with baseline. Adverse effects were 
reported by 51% of patients. The most frequent adverse 
effects were headache (10%), dizziness (10%), diplopia 
(5%), and nasopharyngitis (5%). Adverse effects were mostly 
(97%) of mild to moderate intensity. Eleven patients (3.5%) 
discontinued therapy due to adverse effects, and there were no 
results of laboratory tests raising safety concerns. Sustained 
therapeutic effect, favorable tolerability and safety, and an 
improvement in quality of life and depressive symptoms were 
observed during long-term add-on treatment with once-daily 
ESL in adults with partial-onset seizures.32
Recently, the results of two single-blind studies conducted 
to evaluate the cognitive and psychomotor effects of ESL and 
oxcarbazepine following single and repeated administration 
in healthy volunteers have been reported. The cognitive and 
psychomotor evaluation consisted of several computerized 
and paper-and-pencil measures. ESL and oxcarbazepine had 
similar overall cognitive profiles and did not cause clinically 
relevant cognitive impairment. The incidence of adverse 
events was lower with ESL than with oxcarbazepine.33
Studies in children
Especially in children, there is a need for new, safe, and 
  effective AEDs to extend the therapeutic armamentarium, 
particularly in drug-resistant epilepsy. There is increasing 
literature supporting the fact that about 25% of children 
with epilepsy experience pharmacoresistance or have to 
face significant side effects with AED treatment, represent-
ing a huge burden to young patients and their families.2,6 
Because ESL 800 mg and 1200 mg once daily significantly 
reduced the frequency of partial-onset seizures and showed 
a favorable safety profile when administered as adjunctive 
therapy in adults, a relatively low-dose tablet formulation 
(200 mg) and an oral suspension formulation (50 mg/mL) 
were developed (bioequivalent to the adult tablet formula-
tions).19 To date, only one Phase IIa   clinical trial has explored 
the pharmacokinetics, efficacy, and   tolerability of ESL in 
children.29 In order to study three   different dosage regimes 
in each age group (Group 1: 2–6 years, Group 2: 7–11 years, 
and Group 3: 12–17 years), the   following titration design was 
used: 5 mg/kg/day (weeks 1–4), 15 mg/kg/day (weeks 5–8), 
and 30 mg/kg/day or 1800 mg/day (weeks 9–12). Similar to 
what has been described in adults elsewhere, ESL showed 
extensive first-pass biotransformation to ESL. Accordingly, 
R-licarbazepine and oxcarbazepine were minor metabolites, 
corresponding to 4%–7% and 1%–2% of systemic exposure 
to ESL (comparable with adults). The main metabolic pathway 
for ESL is glucuronidation, and renal excretion comprises 
two-thirds in the unchanged form and one-third as a conjugate 
with glucuronic acid. As a consequence, ESL clearance (and 
clearance of other metabolites) is affected by renal function, 
whereas glucuronidation and/or formation of R-licarbazepine 
or oxcarbazepine seem to be unaffected by liver impairment.34 
As seen in previous studies of other AEDs, clearance in 
children is higher than in adults. This is backed up by a study 
done by Almeida et al showing an age-dependent area under 
the plasma concentration-time curve in the dosing interval 
(AUC0–24) due to faster plasma clearance of eslicarbazepine in 
the younger age groups.29,35 With respect to efficacy, the above-
mentioned study also showed a clear dose-dependent decrease 
in seizure frequency with good tolerability. The median relative 
change in seizure frequency (when   compared with baseline) 
was -28.2%, -24.8%, and -40.6% in Group 1 (5 mg/kg/day, 
15 mg/kg/day, and 30 mg/kg/day, respectively), -11.7%, 5.0%, 
and 12.2% in Group 2, and -17.1%, -31.7%, and -43.1% in 
Group 3. However, with the maximum dosage of 30 mg/kg/
day, adverse effects were mainly related to the nervous sys-
tem and tended to be more frequent and more severe. From a 
pediatrician’s point of view, the lack of an influence of ESL on 
the clearance of sodium valproate, topiramate, phenobarbital, 
carbamazepine, clobazam, gabapentin, and levetiracetam, as 
well as no evidence of QT prolongation, is of importance 
(although the evaluation of electrocardiogram recordings 
during clinical trials showed an increase in PR interval in Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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ESL-treated adults, which was highest in the 1200 mg dose 
group when compared with placebo).29
Drug interactions
In vitro studies
Several in vitro studies did not reveal a major influence of 
warfarin, diazepam, digoxin, phenytoin, and tolbutamide 
on ESL plasma protein binding. As mentioned earlier, stud-
ies with ESL showed no significant induction of CYP1A1, 
CYP3A, and Phase II enzymes (involved in the glucuronida-
tion and sulfation of 7-hydroxy-coumarin) in fresh human 
hepatocytes. The activity of CYP1A2, CYP2A6, CYP2B6, 
CYP2D6, CYP2E1, CYP3A4, and CYP2C9 was not affected, 
and only a moderate inhibitory effect on CYP2C19 (by 38%), 
as well as a moderate increment of UDP-glucuronosyl-
transferase 1A1-mediated ethinylestradiol glucuronidation 
(by 39%), was seen in the presence of ESL in human liver 
microsomes in vitro.36
In vivo studies
To date, two studies have investigated possible interac-
tions within the field of anticonvulsants. First, a multiple-
dose, open-dose, open-label, one-sequence study in two 
parallel groups of 16 healthy male volunteers with ESL 
1200 mg once daily and topiramate 200 mg once daily 
was conducted.37 Second, ESL and lamotrigine plasma 
concentrations and AUC0–24 were calculated in an open-
label study in two parallel groups of 16 healthy subjects.28 
The authors of both studies did not report any significant 
pharmacokinetic interactions and, as a consequence, no 
dose adjustment seems to be required when combining 
these drugs.28,37 The prevalence of epilepsy is similar 
between the genders, and gender-related differences in 
drug response are due to various factors (including per-
centage of body fat and fat free mass, body weight, and 
glomerular filtration rate).38 In a study by Falcao et al in 
12 healthy female and 12 healthy male subjects, gender-
related differences in systemic exposure to ESL were 
marginal and statistically not significant. Therefore, the 
authors concluded that dose adjustments of ESL based on 
gender will not be required.39 Finally, studies concerning 
possible influences of warfarin (at a subtherapeutic level)40 
or food41 on ESL pharmacokinetics in healthy volunteers 
revealed no influence of either on ESL pharmacokinet-
ics, but did show a small and statistically significant 
reduction in systemic exposure to S-warfarin, with no 
effect on R-warfarin, on the International Normalized   
Ratio.40,41
Safety and tolerability
With regard to the safety and tolerability of ESL in patients 
with epilepsy, adverse effects occurred mainly during the 
early treatment phase; intensity was mild to moderate, 
and no significant differences in the incidence of adverse 
effects were apparent between ESL and placebo after six 
weeks of treatment (Table 2).16,24,29,30 Of note, the incidence 
of rash was 0.3% with placebo, 0.5% with ESL 400 mg, 
1.1% with ESL 800 mg, and 3.2% with ESL 1200 mg. 
Furthermore, hyponatremia (,125 mmol/L) was reported 
in four patients, and the incidence of behavioral or psychi-
atric adverse events was ,1%. Because adverse effects in 
patients treated with ESL 800 mg seem to be less likely 
related to the study medication and, as a consequence, 
less likely to lead to discontinuation, a dosage of 800 mg 
appears to show the best benefit to risk ratio. Finally, and 
to summarize the Phase III studies, the overall incidence of 
adverse effects leading to discontinuation of therapy was 
low (4.5% with placebo, 8.7% with ESL 400 mg, 11.6% 
with ESL 800 mg, and 19.3% with ESL 1200 mg). When 
pooling all adults with epilepsy included in the placebo-
controlled studies, 45.3% treated with ESL versus 24.4% 
treated with placebo reported possible treatment-related 
adverse effects. As shown in Table 2, the observed frequency 
of possibly related adverse effects with an incidence .2% 
were dizziness (18.8% versus 5.7%), somnolence (11.2% 
versus 8.4%), nausea (6.5% versus 2.4%), diplopia (6.3% 
versus 1.2%), headache (5.5% versus 2.1%), vomiting 
(4.8% versus 1.2%), abnormal coordination (4.4% versus 
1.8%), blurred vision (3.5% versus 0.9%), vertigo (2.1% 
versus 0%), and fatigue (2.1% versus 1.8%).16,18,24,29,30
In conventional preclinical studies concerning toxicol-
ogy, genotoxicity, reproductive toxicity, and   carcinogenicity, 
no findings of special concern for human use have been 
described to date.18
Conclusion
The overwhelming majority of adults and children suffering 
from monotherapy-resistant partial epilepsy have to be treated 
with adjunctive agents as add-on therapy. However, guidelines 
for AED combination therapy are sparse and often empiric, 
especially in children. Rational polypharmacy has to include 
efficacy, safety and tolerability, toxicology, modes of action, 
and potential drug interactions. The convenience of once-daily 
dosing and a short/simple titration regimen, in combination 
with a favorable efficacy and safety profile, might promote ESL 
as a valid alternative to the current adjunctive AED therapy 
armamentarium for drug-resistant partial seizures.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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The results of previous Phase II and III studies have 
demonstrated and confirmed the efficacy and tolerability of 
ESL 800 mg and 1200 mg once daily as add-on therapy for 
patients with drug-resistant partial-onset seizures.16,24,30,31 
Interestingly, in patients treated with carbamazepine or 
lamotrigine, no differences in ESL efficacy were observed 
when compared with patients not treated with concomitant 
VGSC blockers. Because there is some evidence of improved 
efficacy when combining different VGSC blockers, it seems 
reasonable to evaluate the effect of ESL given together with 
carbamazepine or lamotrigine.42 The precise mechanisms 
underlying the potential efficacy of ESL as adjunctive therapy 
in patients refractory to other VGSC blockers remain unclear 
and seem to be multifactorial (eg, different mechanisms of 
action, pharmacokinetics, and pharmacodynamics for ESL).28 
Hypothetically, patients with drug-resistant epilepsy might 
have altered VGSC protein subunits, leading to diminished 
response to diverse AEDs.43 Furthermore, different neuron 
types may be more or less prone to seizure-induced changes 
in transcriptional plasticity, changing susceptibility of some 
channel proteins to AED treatment.
From a clinical point of view, the incidence of adverse 
effects and possibly adverse effects associated with ESL 
treatment is of outstanding importance, especially in children 
and adolescents. The overall incidence of adverse effects and 
possibly treatment-related adverse effects seems to increase 
with increasing dose, and patients are more susceptible during 
the early phase of treatment. Importantly, and as stated by 
different authors in previous studies, no changes in laboratory 
parameters possibly indicating a safety concern regarding the 
risk for hyponatremia or dyslipidemia, as well as changes in 
body weight, were seen. ESL may not cause QT prolonga-
tion, but the evaluation of electrocardiogram recordings 
during clinical trials showed an increase in PR interval in 
ESL-treated patients, which was highest in the 1200 mg dose 
group compared with the placebo group. Finally, ESL was 
associated with very few psychiatric events, and the incidence 
of rash was low.12,14,16–18,24,29–31,35,40,44,45
It is well known that a fixed portion of epilepsies start in 
childhood, so it is of prime importance to broaden possible 
valuable and safe alternatives to well established AEDs for the 
treatment of drug-resistant partial epileptic seizures in this age 
group. Previous findings suggest a potential antiepileptogenic 
effect of ESL in children and adolescents.29 Dose regimes of 
5–15 mg/kg/day are well tolerated, whereas treatment with a 
higher dosage (30 mg/kg/day) leads to more frequent and more 
severe reporting of adverse effects.29 Clinical efficacy and 
safety trials on ESL are ongoing in children and adolescents, 
and the data already published are far from conclusive, so the 
therapeutic value of ESL in this special population has yet 
to be established.
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